Group 1 - Alibaba Health and Yiling Pharmaceutical signed a strategic cooperation agreement on December 8 [1] - The collaboration focuses on the launch of Yiling's innovative traditional Chinese medicine, Qifang Nasal Tablets, and aims to enhance patient education and chronic disease management [1] - Both companies will jointly establish and operate a "Digital Disease Center for Allergic Rhinitis," creating a comprehensive health management loop covering disease awareness, medical science popularization, treatment recommendations, standardized medication guidance, and long-term follow-up [1]

打喷嚏、流鼻涕、鼻塞……数据显示，过敏性鼻炎发病率高达17%，我国患者人数已逾2亿，且呈持续上升趋势。长期以来，过敏性鼻 炎的临床治疗多以缓解症状为主。虽能暂时控制病情，却难以从根本上调节免疫失衡，导致患者需要反复用药，病程迁延，甚至出现 药物依赖或耐受。 过敏性鼻炎在中医理论中属于"鼻鼽"范畴。鼻鼽的发生与正气不足、外邪侵袭等因素有关，是内外因共同作用的结果。中医认为，过 敏性鼻炎是脏腑失调在鼻腔的反映，多与肺、脾、肾的虚损有关，尤以肺脾气虚为主。很多患者之所以病情反复，正是因为只针对症 状治疗以"治标"，未能调理脏腑机能。 12月7日，以岭药业发布公告称，其独家专利一类新药芪防鼻通片首次被纳入国家医保目录。据悉，芪防鼻通片是治疗持续性变应性鼻 炎（即过敏性鼻炎）的创新中药，为过敏性鼻炎患者提供了治疗新选择。 行业人士表示，从2025年国家基本医疗保险、生育保险和工伤保险药品目录调整的申报细则可见，政策对"真创新"的倾斜力度空前， 强调"真支持创新、支持真创新、支持差异化创新"。据了解，本次目录调整新增114种药品，其中50种为一类创新药。此次芪防鼻通片 被纳入国家医保目录，是对其创新性、临床疗效以及安全性 ...

Core Viewpoint - The Second China Respiratory Health Conference highlighted advancements in respiratory disease prevention and treatment, showcasing innovative drug research by Yiling Pharmaceutical and its new membership in the Traditional Chinese Medicine Respiratory Health Development Community [1][11]. Group 1: Conference Highlights - The conference gathered over 1,200 experts in the respiratory field, including renowned academicians such as Zhong Nanshan and Zhang Boli, to engage in academic exchanges on respiratory disease prevention [1]. - The 2026 Traditional Chinese Medicine Respiratory Health Development Community was officially launched during the conference [3]. Group 2: Yiling Pharmaceutical's Innovations - Yiling Pharmaceutical presented key respiratory products, including Lianhua Qingwen Capsules, Lianhua Qingke Tablets, and Qifang Bitong Tablets, which received significant attention from expert teams [4]. - Lianhua Qingwen Capsules are recognized as an innovative drug for treating colds and influenza, currently included in the traditional Chinese medicine prevention plans of several provinces [4]. - Qifang Bitong Tablets are noted as the first national Class 1 innovative traditional Chinese medicine specifically for treating persistent allergic rhinitis, and have been registered in Macau [4]. Group 3: Research and Development Strategy - Yiling Pharmaceutical has established a unique development model based on the theory of network diseases, integrating theory, clinical practice, new drug development, industry, and education to drive high-quality development [6]. - The company has conducted extensive research on Lianhua Qingwen, resulting in over 120 published SCI papers and inclusion in more than 30 national clinical guidelines [6]. - Yiling Pharmaceutical is focused on building industrial capabilities, ensuring standardized control from raw material cultivation to product distribution, and has set up multiple supply bases across the country [6]. Group 4: Collaborative Efforts - The Traditional Chinese Medicine Respiratory Health Development Community aims to strengthen connections between leading pharmaceutical companies and high-level expert resources, addressing unmet clinical needs and enhancing drug research and application [9]. - Yiling Pharmaceutical's membership in the community will facilitate deep collaboration in evidence-based research and academic promotion, contributing to the development of new productive forces in the respiratory health sector [11].

Core Insights - The article discusses how Shijiazhuang, an old industrial city in Hebei Province, is transforming its economy by focusing on high-quality industrial development and creating five major industrial clusters worth over 100 billion yuan each [1][3]. Industrial Development - Shijiazhuang is revitalizing its economy by optimizing traditional industries, strengthening emerging sectors, and planning for future industries, with a focus on biomedicine, new-generation electronic information, advanced equipment manufacturing, modern food, and modern commercial logistics [1][3]. - The city has established a systematic approach to promote the five major industrial clusters, emphasizing policy guidance, technological innovation, and project construction [3][4]. Electronic Information Industry - The Luquan Economic Development Zone in Shijiazhuang has become a hub for the electronic information industry, hosting major companies and research institutes, and forming six advantageous industrial chains in semiconductor chips, modern communication, and more [2][4]. - The electronic information sector has seen significant growth, with revenue projected to increase from 771.7 billion yuan in 2021 to 1,381.7 billion yuan by 2024, reflecting an annual growth rate of 12.1% [5]. Biomedicine Sector - Shijiazhuang is recognized as a "Pharmaceutical Capital," with major companies like Shijiazhuang Pharmaceutical Group leading the industry. However, challenges remain in core technology and high-end talent acquisition [2][5]. - The biomedicine industry is expected to grow from 771 billion yuan in 2021 to 1,257.2 billion yuan by 2024, with an annual growth rate of 10.8% [5]. Innovation and R&D - The city has invested heavily in R&D, with a budget of 211.6 billion yuan for 2024, aiming to enhance technological innovation and industry integration [6][8]. - Shijiazhuang has established numerous partnerships with universities and research institutions to foster innovation, resulting in over 400 cooperation agreements and the establishment of multiple innovation platforms [7][8]. Talent Development - The city has implemented a talent strategy that includes various incentives and support measures, attracting over 10,000 young talents in 2024 alone [12][15]. - Shijiazhuang has created a favorable environment for talent retention, including housing support and financial incentives, contributing to its recognition as a top city for talent attraction [13][15]. Business Environment - Shijiazhuang is focused on creating a market-oriented, law-based, and international business environment, streamlining administrative processes and enhancing service efficiency for enterprises [9][10]. - The city has introduced measures to protect intellectual property rights, which are crucial for fostering innovation and ensuring fair competition [11].

过敏性鼻炎在中医理论中属于"鼻鼽"范畴。鼻鼽的发生与正气不足、外邪侵袭等因素有关，是内外因共 同作用的结果。中医认为，过敏性鼻炎是脏腑失调在鼻腔的反映，多与肺、脾、肾的虚损有关，尤以肺 脾气虚为主。很多患者之所以病情反复，正是因为只针对症状治疗以"治标"，未能调理脏腑机能。 作为中药1.1类创新药，芪防鼻通片组方基于过敏性鼻炎"肺脾两虚为本、外邪侵袭为标"病机理论化 裁，融合经典名方"玉屏风散"与"辛夷散"，并创新加入高良姜、蝉蜕等特色药材，具有"肺脾同调、标 本兼治"的治疗特点。 12月7日晚间，以岭药业（002603）发布公告，其独家专利一类新药芪防鼻通片首次被纳入《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年)》。作为治疗持续性变应性鼻炎(即过敏性鼻炎)的创 新中药，芪防鼻通片为过敏性鼻炎患者提供了治疗新选择。以岭药业此次共有12个独家品种纳入国家医 保目录。 本次目录调整新增114种药品，其中50种为一类创新药。行业人士表示，从2025年国家基本医疗保险、 生育保险和工伤保险药品目录调整的申报细则可见，政策对"真创新"的倾斜力度空前，强调"真支持创 新、支持真创新、支持差异化创新"。此次 ...

剂型：片剂 证券代码：002603 证券简称：以岭药业 公告编号：2025-051 石家庄以岭药业股份有限公司 关于子公司药品通过谈判纳入 《国家医保目录》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 根据国家医疗保障局网站于2025年12月7日发布的《关于印发〈国家基本医疗保险、生育保险和工伤保 险药品目录〉以及〈商业健康保险创新药品目录〉（2025年）的通知》（医保发【2025】33号），石家 庄以岭药业股份有限公司（以下简称"公司"）全资子公司北京以岭药业有限公司（以下简称"北京以 岭"）独家产品芪防鼻通片通过了医保谈判，首次被纳入《国家基本医疗保险、生育保险和工伤保险药 品目录（2025年）》（以下简称"《国家医保目录》（2025版）"）。具体情况如下： 一、芪防鼻通片进入医保情况 1、药品基本情况 生产厂家：北京以岭药业有限公司 此次公司12个独家专利中药产品列入国家医保目录（2025版），有助于公司进一步推动相关药物的市场 推广、提升销售规模，对公司的长期经营发展具有积极影响，对公司经营业绩的影响暂无法估计，预计 短期内不会对经营业绩产生 ...

创新中药头部企业以岭药业再有一款新药通过谈判，被纳入国家医保目录。 近日，国家医保局公布了《国家基本医疗保险、生育保险和工商保险药品目录(2025年)》，以岭药业独 家品种芪防鼻通片位列其中，成为新进目录的中成药。 以岭药业董事长吴相君在2025创新药高质量发展大会上发言时指出，治疗过敏性鼻炎的芪防鼻通片获批 纳入医保目录，成为以岭药业第5个通过国家医保谈判的创新中药。这既是对企业创新价值的认可，更 是企业沉甸甸的责任。以岭药业将充分发挥理论创新和研发生产优势，全力做好药品供应保障。 行业人士表示，今年医保调整，体现出医保部门对创新药"真支持创新、支持真创新、支持差异化创 新"的导向。 今年1月，以岭药业发布公告称，芪防鼻通片新药注册申请获正式批准，注册分类为中药1.1类创新药； 7月，芪防鼻通片通过澳门特别行政区政府药物监督管理局注册审批，成为首个在澳门获批注册的创新 中药。 芪防鼻通片治疗过敏性鼻炎(肺脾两虚证)有效性和安全性的多中心、随机、双盲、安慰剂平行对照的Ⅲ 期临床试验结果在国际SCI期刊《民族药理学》杂志刊发。研究显示，芪防鼻通片能显著改善过敏性鼻 炎患者的鼻部症状、眼部症状和全身症状。在鼻部症 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002603 证券简称：以岭药业 公告编号：2025-051 石家庄以岭药业股份有限公司 关于子公司药品通过谈判纳入《国家医保目录》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 根据国家医疗保障局网站于2025年12月7日发布的《关于印发〈国家基本医疗保险、生育保险和工伤保 险药品目录〉以及〈商业健康保险创新药品目录〉（2025年）的通知》（医保发【2025】33号），石家 庄以岭药业股份有限公司（以下简称"公司"）全资子公司北京以岭药业有限公司（以下简称"北京以 岭"）独家产品芪防鼻通片通过了医保谈判，首次被纳入《国家基本医疗保险、生育保险和工伤保险药 品目录（2025年）》（以下简称"《国家医保目录》（2025版）"）。具体情况如下： 一、芪防鼻通片进入医保情况 1、药品基本情况 生产厂家：北京以岭药业有限公司 药品注册分类：中药1.1类 是否独家品种：是 药品分类及代码：鼻病 ZF02 医保支付标准：1.78元（0.47g（相当于饮片1.52g）/片） 协议有效期：2026年1月1日至 ...

证券日报网讯12月7日晚间，以岭药业（002603）发布公告称，公司全资子公司北京以岭药业有限公司 独家产品芪防鼻通片通过了医保谈判，首次被纳入《国家基本医疗保险、生育保险和工伤保险药品目录 (2025年)》。 ...

转自：推广 12月7日，以岭药业（002603.SZ）发布公告称，根据国家医疗保障局网站发布的《关于印发〈国家基本医疗 保险、生育保险和工伤保险药品目录〉以及〈商业健康保险创新药品目录〉（2025年）的通知》，其独家产 品芪防鼻通片通过医保谈判，首次被纳入国家医保目录。据悉，芪防鼻通片为首个说明书明确治疗持续性变 应性鼻炎（即过敏性鼻炎）的创新中药，填补临床用药空白。 作为中国中医药行业的领军企业，以岭药业积极响应国家大健康战略号召，始终将研发创新视为企业发展的 核心驱动力，长期保持高强度的研发投入。最新数据显示，2025年前三季度，以岭药业研发费用达5.44亿 元，营收占比达9.27%；2019至2024年间，以岭药业研发投入累计超过50亿元，持续领先于行业平均水平。 这些投入为公司构建了覆盖理论创新、药物研发、循证医学研究到产业化应用的全链条科研体系，为持续创 新提供了坚实保障。 在创新药物研发方面，以岭药业取得了显著成果。目前，公司拥有专利中药17个，覆盖心脑血管系统、感冒 呼吸系统、内分泌系统、肿瘤等8大临床疾病系统，其中12个品种纳入国家医保目录，5个进入国家基本药物 目录，展现了广泛的市场认可度和 ...